

Ref: Akums/Exchange/2026-27/54

October 15, 2026

The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Symbol: AKUMS

Scrip Code: 544222

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Demand Notice

Respected Sir/Ma'am,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**"SEBI LODR Regulations"**), this is to inform you that Pure and Cure Healthcare Private Limited (**"Pure & Cure"**), a wholly-owned subsidiary of Akums Drugs and Pharmaceuticals Limited (**"the Company"**) has received a Demand Notice from National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India dated October 13, 2026 for manufacturing of formulation **"Lanol 1000 mg injection"** 100ml (the product), for our client Hetero Healthcare Limited (**"the client"**), the notice states that the client has fixed MRP of the product, in excess to the prescribed limits under the applicable provisions of The Drugs (Prices Control) Order, 2013.

The above referred demand notice dated October 13, 2026 was issued to three (03) parties which includes Hetero Healthcare Limited as a Marketer, Abaris Healthcare Private Limited and Pure & Cure as a manufacturer (hereinafter referred to be as the **"Parties"** to the demand notice). However, the prime responsibility to respond on the notice is of Hetero Healthcare Limited, being the marketer of the product.

Further in the ordinary course of business, the Company and its subsidiaries execute supply agreements with the marketing entity(ies) containing a clause that marketing entity shall be solely held liable for violation of DPCO provisions; and any penalty, fine, interest and other amount, as may be specified by the regulatory or statutory authority, in the event of any discrepancy found in the maximum retail price of the supplied medicine.

Details of action/order required to be furnished under Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of SEBI LODR Regulations is annexed as **"Annexure-A"**

The above-mentioned demand notice was received by the Company on October 15, 2026 at 11:05 A.M.

This is for your kind information and record.

Thanking You
Yours Faithfully

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Digitally signed by Dharamvir Malik
Date: 2026.10.15 16:25:14 +05'30'

Dharamvir Malik
Company Secretary & Compliance Officer

Encl.: As above

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

Annexure-A

Details of the action/order required to be disclosed as per Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of SEBI LODR Regulations:

Sr. No.	Particulars	Details
1.	Name of the authority	National Pharmaceutical Pricing Authority ("NPPA"), Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India
2.	Nature and details of the action(s) taken, initiated or order(s) passed;	NPPA has issued a Demand Notice of Rs. 52,74,68,193/- on October 13, 2026 against the below mentioned Parties: - Hetero Healthcare Limited - Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of the Company - Abaris Healthcare Private Limited
3.	Date of receipt of direction or order, including any ad-interim or interim order, or any other communication from the authority;	Demand Notice dated October 13, 2026 (received by the concerned person on October 15, 2026 at 11:05 A.M. (IST))
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed;	NPPA has issued the demand notice for manufacturing/marketing of new drug/formulation "Lanol 1000 mg injection" 100ml, -to the below mentioned parties: - Hetero Healthcare Limited - Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of the Company - Abaris Healthcare Private Limited without obtaining prior price approval from Government of India as specified under Section 15 of The Drugs (Prices Control) Order, 2013
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	Total Impact on the parties will be of Rs. 52,74,68,193/- including overcharging amount of Rs. 18,94,80,649/- for the batches manufactured during December 2017 to August 2024 and penalty amount of Rs. 18,94,80,649/- being 100% of the overcharged amount along with interest amount of Rs. 14,85,06,895/- up to October 30, 2026. The prime responsibility to respond on the notice lies with our client.